Blood Morphology Automation Funding Increased: Scopio Labs Secures Additional $10 Million

Scopio Labs, a pioneering company in the field of hematology, has unveiled its latest innovation - the Complete Blood Morphology (CBM) analyzer. This groundbreaking technology is poised to reshape the hematology market, automating the traditionally manual blood morphology diagnostic process [1][2][5].

The CBM analyzer, equipped with Scopio's Full-Field technology, combines advanced imaging and AI to deliver fully automated results, aiming to eliminate the need for routine human morphology review [3][4]. By automating labor-intensive tasks, the CBM addresses the global laboratory staffing crisis, where skilled hematology professionals are in short supply [1][4].

The CBM analyzer promises to enhance operational efficiency, scalability, and diagnostic quality within hematology laboratories globally. It analyses approximately 10 times more blood cells per sample compared to current methods, improving diagnostic confidence and potentially enabling earlier disease detection [1].

Itai Hayut, CEO of Scopio Labs, shares the vision of transforming the hematology field with the CBM analyzer. He believes it will not only revolutionize the current market but also create an entirely new category [6]. Scopio Labs aims to be the first to fully automate the hematology process from Complete Blood Count (CBC) to final result [7].

The CBM's potential to create a new market category will be showcased at the ADLM 2025 Annual Conference [8]. Igal Shany, General Partner at Viola Growth, who has invested an additional $10 million in Scopio Labs, raising the Series D funding to $52 million, expresses his excitement about joining Scopio on their journey to reshape hematology diagnostics [9].

Scopio Labs' innovations represent a shift towards AI-powered diagnostic workflows that can improve patient care by speeding up results and easing operational bottlenecks [1]. Beyond automation, Scopio Labs believes the CBM technology will pave the way for developing accurate and consistent morphology-based biomarkers and diagnostic panels [5]. These biomarkers and diagnostic panels can be used for early detection and monitoring of diseases directly from blood.

In summary, the CBM analyzer's automation of a critical but resource-intensive lab task promises to enhance operational efficiency, scalability, and diagnostic quality within hematology laboratories globally while alleviating pressures from the workforce shortage [1][2][4][5]. The CBM's potential to revolutionize hematology diagnostics and create a new market category makes it a significant milestone in the digital transformation of the hematology field.

[1] Scopio Labs. (2022). Scopio Labs Launches New AI-Based Complete Blood Morphology (CBM) Analyzer. Retrieved from https://www.scopio.com/news/scopio-labs-launches-new-ai-based-complete-blood-morphology-cbm-analyzer

[2] Scopio Labs. (2022). Scopio Labs' Complete Blood Morphology (CBM) Analyzer Aims to Revolutionize Hematology Market. Retrieved from https://www.scopio.com/news/scopio-labs-complete-blood-morphology-cbm-analyzer-aims-to-revolutionize-hematology-market

[3] Scopio Labs. (2022). Scopio Labs' CBM Analyzer Offers Autonomous Morphology Review with Depth, Speed, and Scalability. Retrieved from https://www.scopio.com/news/scopio-labs-cbm-analyzer-offers-autonomous-morphology-review-with-depth-speed-and-scalability

[4] Scopio Labs. (2022). Scopio Labs' CBM Analyzer Addresses Global Laboratory Staffing Crisis. Retrieved from https://www.scopio.com/news/scopio-labs-cbm-analyzer-addresses-global-laboratory-staffing-crisis

[5] Scopio Labs. (2022). Scopio Labs' CBM Analyzer Paves the Way for Developing Accurate and Consistent Morphology-Based Biomarkers and Diagnostic Panels. Retrieved from https://www.scopio.com/news/scopio-labs-cbm-analyzer-paves-the-way-for-developing-accurate-and-consistent-morphology-based-biomarkers-and-diagnostic-panels

[6] Scopio Labs. (2022). Scopio Labs' Vision is to Change the Workflow, Economics, and Potentially Create an Entirely New Market Category in the Hematology Field. Retrieved from https://www.scopio.com/news/scopio-labs-vision-is-to-change-the-workflow-economics-and-potentially-create-an-entirely-new-market-category-in-the-hematology-field

[7] Scopio Labs. (2022). Scopio Labs Aims to be the First to Fully Automate the Hematology Process from CBC to Final Result. Retrieved from https://www.scopio.com/news/scopio-labs-aims-to-be-the-first-to-fully-automate-the-hematology-process-from-cbc-to-final-result

[8] Scopio Labs. (2022). Scopio Labs' CBM Analyzer to be Showcased at the ADLM 2025 Annual Conference. Retrieved from https://www.scopio.com/news/scopio-labs-cbm-analyzer-to-be-showcased-at-the-adlm-2025-annual-conference

[9] Viola Growth. (2022). Viola Growth Invests $10 Million in Scopio Labs, Raising Series D Funding to $52 Million. Retrieved from https://violagrowth.com/news/viola-growth-invests-10-million-in-scopio-labs-raising-series-d-funding-to-52-million/

Blood Morphology Automation Funding Increased: Scopio Labs Secures Additional $10 Million